US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Nanologica deltar i konferenser för preparativ kromatografi

Nanologica kommer att delta i flera kromatografikonferenser under våren i samband med lanseringen av bolagets silika för preparativ kromatografi, NLAB Saga[®].Första konferensen är Purify'22 Chromatography Purification Conclave den 7 april i Hyderabad, Indien, där Nanologicas vd Andreas Bhagwani håller invigningstalet Pharmaceutical Megatrends and the Fundamental Impact of Chromatography och där Nanologicas SVP Chromatography Katarina Alenäs kommer att hålla ett föredrag om New Generation Silica for Peptide Purification. I maj deltar Nanologica på två konferenser i USA:TIDES USA:

Nanologica Recruits VP Drug Development

Nanologica has recruited Ulf Ericsson as VP Drug Development as part of the strategy to enhance focus on the respiratory field and inhalation, within the business area Drug Development. Mr. Ericsson will be responsible for leading the work on developing inhalable pharmaceuticals.To accelerate the development of the NLAB Spiro® inhalation platform, Ulf Ericsson has been recruited as VP Drug Development. The position includes leading efforts and strategy for the development and commercialization of the platform. ” We believe the potential of the NLAB Spiro® platform to be huge, though we

Nanologica’s Patent Application Published

Nanologica’s patent application titled ”New compositions comprising amorphous nanoporous silica particles” has been published.The invention relates to new pharmaceutical compositions, their use as medical treatments and particularly to their administration to the lung to treat lung diseases. Patent applications are published 18 months after the application date and is a step in the process of having a patent granted.   For further information, please contact: Johanna Johansson, IR Manager NanologicaPh: +46 72 211 21 90E-mail: johanna.johansson@nanologica.com   About

Nanologica Publishes Annual Report for 2020

Nanologica hereby announces that the annual report for 2020 has been published. The report is available on the company’s website www.nanologica.com.   For further information, please contact: Johanna Johansson, IR NanologicaPh: +46 72 211 21 90 or e-mail: johanna.johansson@nanologica.com   About Nanologica AB (publ) Nanologica manufactures, develops, and sells nanoporous silica particles for applications within life science. Nanologica is world-leading in controlling the shape, size, porosity, and surface characteristics of silica particles. Through the two business

Nanologica Interim Report Jan-Mar 2021

Summary of the period FINANCIAL OVERVIEW · Net revenue increased by 54 percent to TSEK 5,622 (3,654) · The operating profit and loss for the period was TSEK -6,768 (-6,032) · Profit and loss after tax for the period was TSEK -7,845 (-6,705) · Earnings per share for the period was SEK -0.28 (-0.40) · Cash and cash equivalents at the end of the period amounted to TSEK 57,069 (1,273) SIGNIFICANT EVENTS DURING THE FIRST QUARTER · Test material from upscaling to large-scale production of silica approved · Scientific advisory board within inhalation formed ·

Nanologica Announces Date Change for Annual Report

Nanologica AB (publ) has changed the previously disclosed publication date of April 23, 2021 for the company’s annual report 2020 to May 5, 2021.Financial calendar 2021 Interim report January-March 2021                         April 23, 2021 Annual Report 2020                                                  May 5, 2021 Interim report January-June 2021                             July 9, 2021 Interim report January-September 2021           October 29, 2021 For further information, please contact: Johanna Johansson, IR NanologicaPh: +46 72 211 21 90 or e-mail: johanna.

Nanologica’s Nomination Committee Proposes Thomas Eldered as New Board Member of Nanologica AB

Thomas Eldered, who recently left his position as CEO of Recipharm and who is Nanologica’s largest shareholder, is proposed as new member of the Board of Directors to be elected at the Annual General Meeting on May 27.Thomas Eldered holds a M.Sc. in Industrial and Management Engineering from Linköping Institute of Technology and is the co-founder of Recipharm AB, where he was also the CEO from 2008–2021. Before that, Thomas was the Vice President of Recip AB 1995–2007. The Nomination Committee is in addition proposing re-election of Gisela Sitbon, Mattias Bengtsson, Eva Byröd, Tomas

Nanologica Announces Date Change for Interim Reports for First and Second Quarter

Nanologica AB (publ) has changed the previously disclosed publication date of May 7, 2021 for the Company’s interim report for the first quarter 2021 to April 23, 2021.In addition, the date for the interim report for the second quarter 2021 has been changed from August 27, 2021 to July 9, 2021. Financial calendar 2021 Interim report January-March 2021                          April 23, 2021Annual Report 2020                                                  April 23, 2021Interim report January-June 2021                            July 9, 2021Interim report January-September 2021

Nanologica to Attend BIO-Europe Spring March 22-25 for Partnering Discussions

Nanologica will be attending BIO-Europe Spring, March 22-25, to meet with potential pharmaceutical partners regarding drug delivery applications using NLAB Spiro[®] and NLAB Silica™.Nanologica’s drug delivery platforms NLAB Spiro[®] and NLAB Silica™ consists of nanoporous particles where APIs can be placed inside the pores. By loading the API into the particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the technical benefits of using Nanologica’s drug delivery platforms include improving solubility,

Year-End Report Nanologica 2020

SUMMARY OF THE PERIODFINANCIAL OVERVIEW · Net revenue increased by 75 percent to TSEK 16 135 (9 227) in total, of which the fourth quarter TSEK 6 071 (2 731) · The operating result for the period was TSEK -19 571 (-20 066), of which the fourth quarter TSEK -3 648 (-6 260) · Loss for the period was TSEK -22 199 (-21 080), of which the fourth quarter TSEK -5 427 (-6 855) · Loss per share for the period was SEK -0,93 (-1,27), of which the fourth quarter SEK -0,20 (-0,41) · Cash and cash equivalents at the end of the period amounted to TSEK  66 364 (1 176) SIGNIFICANT EVENTS

Change in Number of Shares in Nanologica AB

The number of shares in Nanologica AB (publ) has changed during the month of February as a result of options from the stock option program 2018/21 being exercised.A share-based incentive program of a maximum of 483 883 options was decided by the Annual General Meeting May 31, 2018. The program expires July 1st, 2021 and the options may be exercised any time before that to a strike price of SEK 9.3. According to the Financial Instruments Trading Act (1991:980), any changes in the total number of shares in Swedish publicly traded companies shall be made public per the last day of trade of the

Nanologica Recruits SVP Sales and Senior Advisor for Chromatography

Nanologica has recruited Dr. PK Dutta as SVP Sales and Senior Advisor for the business area of chromatography. Dr. PK Dutta will focus on sales growth of Nanologica’s chromatography products primarily in the US.To accelerate sales of chromatography products following the successful upscaling of Nanologica’s silica towards ton scale, Dr. Dutta has been recruited as SVP Sales and Senior Advisor. The position includes leading efforts and strategy for market growth in direct and indirect sales in North America. ” Having approved the products from our ton scale manufacturing facility at

Nanologica Signs Collaboration Agreement with Zentiva for the use of NLAB Drug Delivery Platforms

A collaboration agreement for the use of the NLAB drug delivery platforms has been signed with Zentiva, a pharmaceutical company operating in Europe and beyond. The aim of this collaboration agreement is to simplify the contract process for future product-specific agreements.The agreement gives Zentiva the right to use the NLAB drug delivery platforms for multiple drug development projects. Project specific agreements will be signed separately under this collaboration agreement. ” We first met Zentiva during BIO-Europe in 2019. Since then, we have had a continuous dialogue as they see

Nanologica Engages Scientific Advisors within Inhalation

Nanologica AB has engaged two senior scientific advisors within the field of respiratory drug delivery, for the purpose of advancing the NLAB Spiro™ inhalation platform further.Dr. John Pritchard has more than 40 years of experience from the inhalation industry working in various positions, leading and managing global portfolios of technology projects from discovery to market, at for example GlaxoSmithKline, 3M Health Care Ltd and as Head of Respiratory Project Management at AstraZeneca. His vast experience from the respiratory drug delivery field also includes serving on a Technical

Test Material from Large Scale Production Delivered

The first samples of test material from the upscaling to large-scale production of Nanologica’s silica have been delivered.Upscaling to large-scale production of Nanologica’s silica started in July 2019. The silica is produced according to Nanologica’s proprietary methods at the contract manufacturer Sterling Pharma Solutions in the UK. The first samples of test material have now been delivered. ” It is very pleasing to having received the first test material from the large-scale production. This shows our production method is scalable and gives us confidence going into ton scale

Nanologica to attend conferences devoted to respiratory drug delivery

Nanologica’s technology platform for drug delivery has developed to include inhalation as administration route. Great interest has been shown in the platform and Nanologica now aims to further discuss the platform with leaders in the field and with potential partners.On Dec 5-6, Nanologica will take part in the inaugural Respiratory Drug Delivery conference in London, UK. The purpose of the conference is to bring together clinical researchers, respiratory drug manufacturers and solution providers to discuss the current research and developments in providing appropriate long-term treatments

Nanologica acknowledges World Diabetes Day

November 14 marks the date for the World Diabetes Day. For Nanologica, the day is highly relevant as the Company is working with solutions for diabetes related issues in both its business areas.Diabetes is a disease affecting more than 400 million people worldwide, a number that is expected to increase to more than 640 million by 2040. In 2015 diabetes was the cause of 5 million deaths and more than 200 million people are estimated to be affected by the disease without knowing it. Most diabetic patients require insulin to be able to survive, but as insulin is expensive, many cannot afford

Nanologica to attend BIO-Europe Nov. 11-13 in Hamburg for partnering discussions

Nanologica will be attending BIO-Europe in Hamburg, Nov. 11-13, to meet with potential pharmaceutical partners regarding co-development and licensing of NIC-001, Nanologica’s drug candidate for treating gastroparesis, as well as seeking partnership for further drug delivery applications using NLAB Silica™.Nanologica’s drug delivery platform NLAB Silica™ consists of nanoporous amorphous proprietary silica particles. By loading the API in NLAB Silica™ particles, Nanologica can overcome several of the challenges that prevent or limit effective treatment of many serious diseases. Some of the

Nouryon Nordic prize winner Dr Sabrina Valetti

Nanologica proudly acknowledges Dr Sabrina Valetti as recipient of the Nouryon Nordic prize for her research Mesoporous silica particles for enhanced and controlled drug release in severe bacterial infection. The Nouryon Nordic Prize acknowledges outstanding research in physical chemistry and colloid science.Dr Valetti conducted her research on mesoporous silica particles at Nanologica AB during 2014-2016, as recipient of the prestigious Marie Curie Post Doc fellowship. Together with her supervisor Adj. Prof Adam Feiler, CTO Nanologica, the work focused on improving drug bioavailability

Nanologica and Teva enter into a Feasibility Study Agreement

Nanologica to perform a feasibility study for Teva Pharmaceuticals on the development of a customized drug delivery system.Nanologica has today announced that it enters into a Feasibility Study Agreement with Teva. Under the agreement, Nanologica will develop a customized drug delivery system for an undisclosed drug to improve chemical characteristics of the drug for increased drug uptake into the patient’s body. The scope of the project is a perfect match to Nanologica’s technology and key knowledge on how to use nanoporous silica as drug carriers for oral administration. ”With

Nanologica enters into research collaboration with GSK

Nanologica has signed a Services Agreement with GSK to apply its expertise in nanoporous materials and customized drug delivery systems to advance the development of new technology platforms for early stage development projects.”We are excited about the collaboration with GSK. This is an early, but interesting project with the possibility to unlock new approaches to personalized medicine. It is a great opportunity for Nanologica to contribute to this field,” says Nanologica’s CEO Andreas Bhagwani. This paid development project is in line with Nanologica’s strategy in the business area

There are no items matching the current filter
There are no more items matching the current filter
Back to top